Mylan N.V. (MYL)
Symbol Info
Listed Symbol MYL
Name Mylan N.V.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $11,268,700,000
Latest Fiscal EPS $0.68
Price Info
21 Day Moving Average $19.8167
21 Day EMA $20.326860
50 Day Moving Average $19.4030
50 Day EMA $19.862210
200 Day EMA $24.149200
200 Day Moving Average 24.556350
52 Week High $39.59
52 Week Low $16.63
52 Week Change $-42.981102
Alpha -0.020087
Beta 1.8263
Standard Deviation 0.107725
R2 0.341617
Periods 60
Share Information
10 Day Average Volume 5,426,942
20 Day Average Volume 5,195,332
30 Day Average Volume 6,225,085
50 Day Average Volume 7,563,323
Outstanding Shares 515,869,921
Float Shares 512,473,141
Percent Float 99.34%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 1,175
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 67,449,442
Institute Holdings Percent -
Institute Sold Previous 3 Months 76,768,333
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 10
Insider Holdings Percent 0.70%
Insider Sold Previous 3 Months -
Insiders Shares Owned 3,396,780
Price Change
7 Day Price Change $1.1700001
7 Day Percent Change 5.70%
21 Day Price Change $3.3500004
21 Day Percent Change 18.27%
30 Day Price Change $1.9700012
30 Day Percent Change 9.99%
Month To Date Price Change $2.2200
Month To Date Percent 11.40%
90 Day Price Change $4.310001
90 Day Percent Change 24.80%
Quarter To Date $2.650000
Quarter To Date Percent 13.92%
180 Day Price Change $-5.779999
180 Day Percent Change -21.04%
200 Day Price Change $-9.279999
200 Day Percent Change -29.96%
Year To Date $-5.709999
Year To Date Percent -20.84%
Profile
Description Registered in the Netherlands, Mylan is a leading generic drugmaker, with roughly 55 manufacturing and R&D facilities. Although the company was formed in 1961, the company's position as the second- largest generic company was largely attributable to the acquisition of Matrix Laboratories and generics business of Germany-based Merck KGaA. Mylan has a portfolio of more than 7,500 generic, specialty, and over-the-counter active ingredients and medicines and is predominantly recognized for manufacturing the EpiPen (treatment for anaphylaxis), which was acquired through the Merk KGaA transaction.
Details
Issue Type CS
Market Cap $11,189,218,586
Sec Type EQS
Auditor Deloitte & Touche LLP
Total Shares Outstanding 515,869,921
CEO Heather Bresch
Employees 35,000
Last Audit UQ
Classification
CIK 0001623613
Industry Drug Manufacturers
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address Building 4, Trident Place
Mosquito Way
Hatfield, Hertfordshire AL10 9UL
Website http://www.mylan.com
Facisimile +44 1707261803
Telephone +44 1707853000
Email InvestorRelations@mylan.com
Key Ratios
Profitability
EBIT Margin 5.60
EBITDA Margin 24.3
Pre-Tax Profit Margin 6.7
Profit Margin Cont 0.27
Gross Margin 33.60
Profit Margin TOT 0.27
Income Statements
Revenue $12,954,400,000
Revenue Per Share $25.1118
Revenue 3 Years $5.12
Revenue 5 Years $10.59
Valuation Measures
PE Ratio 370.70
Enterprise Value $24,684,047,043
Price To Sales 0.863739
Price To Free Cash 11.000000
PE High Last 5 Years 49.3
Price To Book 1.0
Price To Cash Flow 6.0
PE Low Last 5 Years 16.0
Price To Tangible Book -1.1
Financial Strength
Total Debt To Equity 1.1
Int Coverage 1.2
Current Ratio 1.4
Leverage Ratio 2.7
Quick Ratio 0.7
Long Term Debt To Capital 0.52
Assets
Receivables Turnover 1.7
Invoice Turnover 2.80
Assets Turnover 0.20
Management Effectiveness
Return Assets 0.11
Return On Equity 0.29
Return On Capital 1.78
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type Cash


Your Recent History
NASDAQ
MYL
Mylan NV
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.